{"id":"quetiapine-immediate-release","safety":{"commonSideEffects":[{"rate":"18-27","effect":"Somnolence/sedation"},{"rate":"9-16","effect":"Dry mouth"},{"rate":"10-18","effect":"Dizziness"},{"rate":"13-19","effect":"Headache"},{"rate":"5-23","effect":"Weight gain"},{"rate":"7-9","effect":"Orthostatic hypotension"},{"rate":"6-8","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which are implicated in psychosis and mood dysregulation. It also has activity at other receptors including histamine H1 and adrenergic receptors, contributing to its sedating properties and broader psychiatric effects.","oneSentence":"Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:27.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07401836","phase":"NA","title":"Standardized Sleep Bundle for Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"Horizon Health Network","startDate":"2026-03","conditions":"Sleep","enrollment":20},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04164758","phase":"PHASE2","title":"Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine","status":"TERMINATED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2019-10-23","conditions":"Parkinson's Disease","enrollment":11},{"nctId":"NCT00229645","phase":"PHASE4","title":"A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety","status":"COMPLETED","sponsor":"Dr Alexander McIntyre Inc.","startDate":"2003-11","conditions":"Major Depression With Comorbid Anxiety Symptoms","enrollment":60},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT00227305","phase":"PHASE3","title":"Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":381},{"nctId":"NCT00206115","phase":"PHASE3","title":"SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenic Disorder","enrollment":535},{"nctId":"NCT00090324","phase":"PHASE3","title":"Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Schizophrenia","enrollment":249},{"nctId":"NCT00090311","phase":"PHASE3","title":"Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-07","conditions":"Bipolar Disorder","enrollment":220},{"nctId":"NCT00206128","phase":"PHASE3","title":"Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenia","enrollment":454},{"nctId":"NCT01213836","phase":"PHASE4","title":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00926393","phase":"PHASE4","title":"Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Bipolar Depression","enrollment":139},{"nctId":"NCT01239589","phase":"","title":"European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Acute Bipolar Manic Episode","enrollment":1280},{"nctId":"NCT01214135","phase":"","title":"A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT00832221","phase":"PHASE1","title":"Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Depression","enrollment":10},{"nctId":"NCT00702676","phase":"PHASE1","title":"Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Healthy Volunteers","enrollment":63},{"nctId":"NCT00254787","phase":"PHASE2","title":"Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-06","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT00523601","phase":"","title":"Quetiapine Efficacy in Bipolar Depression Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Bipolar Depression","enrollment":2000},{"nctId":"NCT00457899","phase":"PHASE3","title":"Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Schizophrenia, Schizoaffective Disorders, Psychotic Disorders","enrollment":234}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DIZZINESS"},{"count":1,"reaction":"ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS"},{"count":1,"reaction":"BEZOAR"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"GAIT DISTURBANCE"},{"count":1,"reaction":"INSOMNIA"},{"count":1,"reaction":"INTENTIONAL OVERDOSE"},{"count":1,"reaction":"MUSCLE RIGIDITY"}],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seroquel IR"],"phase":"marketed","status":"active","brandName":"Quetiapine Immediate Release","genericName":"Quetiapine Immediate Release","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}